We are live on ! Find out more
TCM

Tekla Capital Management Portfolio holdings

AUM $2.56B
1-Year Est. Return 18.15%
This Fund
S&P 500
This Quarter Est. Return
-9.4%
1 Year Est. Return
+18.15%
3 Year Est. Return
+62.51%
5 Year Est. Return
+140.53%
10 Year Est. Return
+502.91%
AUM
$2.21B
AUM Growth
-$432M
Cap. Flow
-$92.5M
Cap. Flow %
-4.18%
Top 10 Hldgs %
42.68%
Holding
227
New
13
Increased
52
Reduced
76
Closed
10

Top Buys

Rank Stock Value
1
BIIB icon
Biogen
BIIB
+$14.4M
2
CNC icon
Centene
CNC
+$8.41M
3
SNY icon
Sanofi
SNY
+$6.73M
4
LLY icon
Eli Lilly
LLY
+$6.66M
5
IQV icon
IQVIA
IQV
+$6.64M

Top Sells

Rank Stock Value
1
MRK icon
Merck
MRK
+$15.5M
2
REGN icon
Regeneron Pharmaceuticals
REGN
+$12.5M
3
JNJ icon
Johnson & Johnson
JNJ
+$11.1M
4
MDCO
Medicines Co
MDCO
+$10.3M
5
ELV icon
Elevance Health
ELV
+$9.94M

Sector Composition

Rank Sector Weight
1 Healthcare 95.66%
2 Real Estate 2.76%
Name Market Value Portfolio Weight Shares or Principal Change
in Stake 		Capital Flow
BLUE
101
DELISTED
bluebird bio
BLUE
$3.87M 0.18%
6,500
-887
-12% -$864K
A icon
102
Agilent Technologies
A
$39.7B
$3.76M 0.17%
52,525
+25,200
+92% +$2.02M
FATE icon
103
Fate Therapeutics
FATE
$303M
$3.68M 0.17%
165,672
– –
XLRN
104
DELISTED
Acceleron Pharma
XLRN
$3.65M 0.17%
40,606
-45,707
-53% -$3.55M
DOC icon
105
Healthpeak Properties
DOC
$15.1B
$3.59M 0.16%
150,392
+21,855
+17% +$712K
SNN icon
106
Smith & Nephew
SNN
$12.6B
$3.57M 0.16%
99,560
– –
ARDX icon
107
Ardelyx
ARDX
$1.2B
$3.46M 0.16%
607,698
– –
FOLD
108
DELISTED
Amicus Therapeutics
FOLD
$3.41M 0.15%
368,960
– –
PVLA
109
Palvella Therapeutics
PVLA
$2.18B
$3.3M 0.15%
18,116
– –
CRSP icon
110
CRISPR Therapeutics
CRSP
$5.14B
$3.23M 0.15%
76,222
– –
EPZM
111
DELISTED
Epizyme, Inc
EPZM
$3.22M 0.15%
207,752
-145,350
-41% -$3.12M
TAK icon
112
Takeda Pharmaceutical
TAK
$52.9B
$3.19M 0.14%
210,146
– –
GMAB icon
113
Genmab
GMAB
$18B
$3.14M 0.14%
148,148
+131,628
+797% +$2.93M
HR
114
DELISTED
Healthcare Realty Trust Incorporated
HR
$2.9M 0.13%
104,024
+20,395
+24% +$692K
RVTY icon
115
Revvity
RVTY
$12.8B
$2.9M 0.13%
38,494
+19,483
+102% +$1.73M
RCKT icon
116
Rocket Pharmaceuticals
RCKT
$379M
$2.9M 0.13%
207,555
– –
ALLK
117
DELISTED
Allakos
ALLK
$2.87M 0.13%
64,397
-6,999
-10% -$479K
SAGE
118
DELISTED
Sage Therapeutics
SAGE
$2.76M 0.12%
96,211
– –
INGN icon
119
Inogen
INGN
$177M
$2.66M 0.12%
51,406
– –
RMD icon
120
ResMed
RMD
$32.4B
$2.63M 0.12%
17,831
-9,944
-36% -$1.58M
EDIT icon
121
Editas Medicine
EDIT
$428M
$2.58M 0.12%
130,201
-17,738
-12% -$447K
DCPH
122
DELISTED
Deciphera Pharmaceuticals, Inc. Common Stock
DCPH
$2.53M 0.11%
61,370
– –
MNTA
123
DELISTED
Momenta Pharmaceuticals, Inc.
MNTA
$2.48M 0.11%
+91,316
New +$2.54M
ALKS icon
124
Alkermes
ALKS
$8.33B
$2.45M 0.11%
169,930
-28,118
-14% -$502K
AMRN
125
Amarin Corp
AMRN
$302M
$2.42M 0.11%
30,190
+9,784
+48% +$3.25M
3 4
5
6 7

Similar funds

EST
EA Series Trust Havertown, Pennsylvania $2.84B AUM
VIA
Vident Investment Advisory Alpharetta, Georgia $2.9B AUM 24.67% 1-Year Est. Return
AWS
AJ Wealth Strategies New York $2.07B AUM 10.86% 1-Year Est. Return
JP
Jana Partners New York $1.34B AUM 4.95% 1-Year Est. Return
VCM
Vigilant Capital Management Portland, Maine $1.34B AUM 15.33% 1-Year Est. Return
FCFS
First Command Financial Services Fort Worth, Texas $1.06B AUM 10.74% 1-Year Est. Return
FCB
First Command Bank Fort Worth, Texas $1.06B AUM 10.74% 1-Year Est. Return
BWM
BerganKDV Wealth Management Bloomington, Minnesota $1,000M AUM 9.95% 1-Year Est. Return

Tekla Capital Management's Q1 2020 Portfolio in Review

As of Q1 2020, Tekla Capital Management held 227 positions worth $2.21B, down 16% from $2.64B the previous quarter. Its ten largest holdings account for 43% of the portfolio.

Tekla Capital Management withdrew a net $92.5M in Q1 2020, closing 10 positions and reducing 76 holdings. Its most notable exit was Medicines Co, an estimated $10.3M position sold in full.

By sector, the portfolio is most concentrated in Healthcare at 96% of assets, up from 94% a quarter earlier, followed by Real Estate.

Against the trend, Tekla Capital Management opened a new position in Moderna worth $7.61M.

  • Tekla Capital Management's largest Q1 2020 buy was Moderna: 254,146 shares worth $7.61M.
  • Tekla Capital Management added most to Biogen in Q1 2020, an estimated $14.4M increase.
  • Tekla Capital Management's biggest Q1 2020 reduction was Merck, cutting an estimated $15.5M.
  • Tekla Capital Management fully exited Medicines Co in Q1 2020, selling an estimated $10.3M.
  • Tekla Capital Management's ten largest holdings make up 43% of its $2.21B portfolio in Q1 2020.
  • Tekla Capital Management opened 13 new positions and closed 10 in Q1 2020.
  • Tekla Capital Management's portfolio value fell 16% quarter-over-quarter to $2.21B.

Based on Tekla Capital Management's 13F filing for Q1 2020, filed 14 May 2020.